BioSyent Azione

BioSyent Debiti verso fornitori

Il Debiti Commerciali di BioSyent (RX.V) al 16 ago 2026 è 6,15 Mio. CAD. L'anno precedente, Debiti Commerciali era 4,00 Mio. CAD — una variazione del 53,74% (superiore).

Debiti verso fornitori

6,15 Mio.CAD

YoY

53,74%

Ultimo aggiornamento:

Debiti Commerciali di BioSyent ammonta a 2026 6,15 Mio. CAD. Debiti Commerciali di BioSyent ammontava a 2025 4,00 Mio. CAD. Diminuisce del 53,74% superiore rispetto all'anno precedente.
Access this data via the Eulerpool API

BioSyent Analisi delle Azioni

Cosa fa BioSyent? Biosyent Inc is a Canadian pharmaceutical company founded in 2004. The company's headquarters are located in Mississauga, Ontario. Biosyent is listed on the Toronto Stock Exchange and has a market capitalization of approximately 140 million Canadian dollars. The company's business model is based on acquiring domestic pharmaceutical and nutraceutical products and marketing them in Canada. Biosyent operates in two main divisions: Pharma and Nutraceuticals. The Pharma division includes products such as RepaGyn, a vaginal gel for treating dryness and irritation during menopause, as well as the antiemetic Setofilm/Tablets for the prevention and treatment of nausea and vomiting. The Nutraceutical division includes products such as FeraMAX, a supplement that increases iron in the diet and helps prevent the development of anemia. Biosyent also offers vitamin-rich dietary supplements such as Aerobic Oxygen and Calm Biotic, targeting health-conscious customers. Another important area of Biosyent is Hospital Specialty Pharmaceuticals, targeting hospitals and healthcare facilities. This includes products like Cysview and Cysview Kit, used to detect non-muscle invasive bladder cancer and improve fluorescence during cystoscopy. Biosyent also offers infusion sets designed for intravenous medication administration. Overall, Biosyent has more than 20 products in various categories including women's and men's health, ophthalmology, immunology, and oncology. Over the years, Biosyent Inc has received various awards for its products and business practices. In 2012, the company received the Bio-Wellness Award for its flagship product, RepaGyn. While Biosyent has ambitions to expand its presence in international markets, the company remains primarily focused on the Canadian market. Biosyent relies mainly on a low-cost marketing strategy that aims to directly target patients in order to market its products in a simple way. Overall, Biosyent has a strong market position in Canada and a portfolio of well-established products. The company has a successful history and appears ready for the future with a strong pipeline and a growing presence in the Canadian market. BioSyent è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su BioSyent azioni

Debiti Commerciali di BioSyent è 6,15 Mio. CAD nel 2026.

Il Debiti Commerciali di BioSyent è passato da 4,00 Mio. CAD a 6,15 Mio. CAD, con una variazione del 53,74 %. Il valore è superiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del BioSyent di Debiti Commerciali dal 2006, con valori annuali, grafici e analisi dettagliate.

I debiti commerciali rappresentano il denaro dovuto ai fornitori per beni e servizi ricevuti. È un componente fondamentale della gestione del capitale di esercizio.

Il CAD di Debiti Commerciali è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il BioSyent di Debiti Commerciali storicamente e in tempo reale.

Access this data via the Eulerpool API

Bilancio — BioSyent

Tutte le Metriche Finanziarie — BioSyent